Beyond Air (XAIR) AI Stock Analysis

• Market Cap: $14.76M
• Dividend Yield: N/A
• Average Volume (3M): 6.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: 168.20%
• EPS Growth: 63.41%
• Country: US
• Employees: 107
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 7,934,767
• 10 Day Avg. Volume: 277,876
• 30 Day Avg. Volume: 6,042,452
• PEG Ratio: <0.01
• Price to Book (P/B): 1.36
• Price to Sales (P/S): 4.98
• P/FCF Ratio: -0.42
• Enterprise Value/Market Cap: 1.55
• Enterprise Value/Revenue: 4.77
• Enterprise Value/Gross Profit: -19.42
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $10.33
• Price Target Upside: 486.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.00 ▲(13.64% Upside)

Beyond Air's overall stock score reflects significant financial challenges despite strong revenue growth. The company's financial performance is hindered by negative profitability and cash flow issues, which are the most significant factors impacting the score. Technical analysis indicates bearish momentum, further weighing on the stock. While the earnings call provided some positive insights, ongoing net losses and valuation concerns limit the overall score.

Positive Factors

Revenue Growth

The substantial revenue growth indicates strong market adoption of Beyond Air's products, suggesting a robust demand for its innovative therapies, which could drive long-term business expansion and sustainability.

Cost Management

Effective cost management through significant reductions in operating expenses enhances profitability, allowing Beyond Air to allocate resources efficiently and improve its financial health over time.

International Expansion

Expanding international presence with distribution partners in over 30 countries positions Beyond Air for global growth, increasing its market reach and potential revenue streams.

Negative Factors

Profitability Challenges

Ongoing net losses highlight profitability challenges, which could strain financial resources and hinder long-term growth unless addressed through improved cost management and revenue enhancement.

Cash Flow Issues

Deteriorating cash generation capabilities, as indicated by negative cash flow growth, may impact Beyond Air's ability to fund operations and invest in growth opportunities, posing a risk to financial stability.

International Sales Scaling

Challenges in scaling international sales could delay revenue realization from new markets, affecting Beyond Air's growth trajectory and international market penetration efforts.

Beyond Air Business Overview & Revenue Model

Company Description

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

How the Company Makes Money

Beyond Air generates revenue primarily through the sale of its proprietary nitric oxide delivery systems and related products. The company's key revenue streams include direct sales of its devices to hospitals and healthcare providers, as well as potential licensing agreements for its technologies. Additionally, Beyond Air may benefit from partnerships with pharmaceutical companies for the development of combination therapies. The ongoing commercialization of its products and the expansion into new markets are critical factors contributing to its earnings, alongside potential reimbursement strategies with healthcare payers.

Beyond Air Financial Statement Overview

Summary

Beyond Air is experiencing revenue growth but faces significant profitability and cash flow challenges. The company has a stable financial structure with low leverage, yet struggles with negative margins and cash flows. Strategic improvements in cost management and operational efficiency are crucial for enhancing profitability and ensuring sustainable growth.

Income Statement

Beyond Air's income statement reveals significant challenges. The company has experienced a substantial revenue growth rate of 29.07% in the TTM, indicating potential market traction. However, profitability remains a concern with negative gross profit, net profit, and EBIT margins, reflecting ongoing operational inefficiencies and high costs relative to revenue. The consistent negative margins highlight the need for strategic cost management and revenue enhancement.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.21 in the TTM, suggesting manageable leverage levels. However, the return on equity is significantly negative, indicating that the company is not generating sufficient returns on shareholder investments. The equity ratio stands at 35.31%, showing a moderate reliance on equity financing. Overall, the balance sheet reflects a stable financial structure but with poor profitability metrics.

Cash Flow

Cash flow analysis indicates a challenging environment with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with reported losses. However, the negative free cash flow growth rate of -18.43% in the TTM highlights deteriorating cash generation capabilities. The company needs to improve its cash flow management to support its operations and growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.78M	3.71M	1.16M	0.00	0.00	873.00K
Gross Profit	-1.18M	-1.66M	-1.31M	-555.00K	-588.00K	873.00K
EBITDA	-37.23M	-41.89M	-59.03M	-58.20M	-42.70M	-22.02M
Net Income	-42.12M	-46.63M	-60.24M	-55.82M	-43.18M	-22.88M
Balance Sheet
Total Assets	28.11M	30.06M	56.96M	68.75M	99.20M	40.52M
Cash, Cash Equivalents and Short-Term Investments	6.63M	6.92M	34.47M	45.88M	80.24M	34.63M
Total Debt	11.69M	11.69M	17.84M	3.59M	3.49M	6.93M
Total Liabilities	17.71M	15.72M	29.77M	26.72M	20.99M	10.06M
Stockholders Equity	9.93M	13.58M	25.05M	37.91M	72.70M	30.46M
Cash Flow
Free Cash Flow	-35.97M	-44.10M	-61.76M	-36.89M	-24.58M	-20.53M
Operating Cash Flow	-32.56M	-38.22M	-56.01M	-33.01M	-23.13M	-19.64M
Investing Cash Flow	12.37M	14.90M	-12.23M	-20.59M	-1.45M	-890.00K
Financing Cash Flow	20.98M	16.65M	43.17M	2.70M	79.45M	30.33M

Beyond Air Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XAIR, the sentiment is Negative. The current price of 1.76 is below the 20-day moving average (MA) of 2.16, below the 50-day MA of 2.31, and below the 200-day MA of 3.96, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 33.53 is Neutral, neither overbought nor oversold. The STOCH value of 26.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XAIR.

Beyond Air Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYPR	47 Neutral	$96.28M	-1.97	-77.26%	―	-9.59%	8.78%
TLSI	47 Neutral	$218.92M	―	―	―	45.50%	53.07%
LUNG	46 Neutral	$70.08M	-1.20	-66.88%	―	18.24%	4.81%
XAIR	46 Neutral	$14.76M	-0.16	-323.27%	―	168.20%	63.41%
COCH	40 Underperform	$20.88M	-0.54	―	―	-26.49%	-91.23%
IINN	35 Underperform	$24.72M	-2.09	―	―	―	―

Beyond Air Corporate Events

Beyond Air Announces New Warrant Agreement

On September 8, 2025, Beyond Air announced an agreement with holders of existing warrants to purchase 1,439,126 shares at a reduced price, generating approximately $3.18 million in gross proceeds. In return, the company will issue new unregistered warrants for 719,561 shares. The proceeds will support clinical and pre-clinical programs, with the transaction closing expected on September 9, 2025.

The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Beyond Air’s NeuroNOS Gains FDA Orphan Drug Status

On September 8, 2025, Beyond Air‘s subsidiary, NeuroNOS, received Orphan Drug Designation from the FDA for its investigational therapy, BA-101, aimed at treating Glioblastoma, a highly aggressive brain cancer. This designation highlights the company’s commitment to addressing rare neurological conditions and marks its entry into oncology, offering potential market exclusivity and incentives for further development.

The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Beyond Air’s Earnings Call Highlights Growth and Challenges

Beyond Air’s recent earnings call revealed a positive sentiment overall, driven by strong financial growth and operational improvements. The company has made significant strides through strategic partnerships and international expansion, although challenges in market penetration and maintaining innovation with reduced R&D expenditures were acknowledged. Despite these hurdles, the outlook remains optimistic with substantial growth potential anticipated in the upcoming quarters.

Beyond Air Reports Strong Revenue Growth in Q1 2026

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company that focuses on utilizing nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors. The company has developed the LungFit system, which is approved for use in the treatment of hypoxic respiratory failure in neonates.